Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer @NEJM https://t.co/vHhF5XoUZE 👉Low-dose aspirin resulted in a significantly lower risk of recurrence w/ hotspot mutations 👉similar benefit w/ other alterations in PI3K pathway 🧐I would take it... @myESMO

A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer in @ESMO_Open. A new “Risk Stratification”score based on clinical/pathological and radiomics features outperforming conventional methods. https://t.co/3Vq6edoOeV

🔥Can we predict relapse in colon cancer before surgery❓Together with @HMar_research and @QuibimBiomarker, we built an AI-radiomics model that identifies high-risk patients from pre-op CT scans. 📌Published in @ESMO_Open 🔗 https://t.co/F8j3uyOVNA

AMIGOS: LA FAMILIA QUE NO ELIGES #AmigosDelParque

Tres investigadores @HMar_research reciben ayudas a la #investigación de @ContraCancerBCN Lluís Espinosa, @JLinaresA y @ClaraMontagut lideran los proyectos. @SoniaServitja participa en un estudio liderado por @IRBBarcelona #CancerResearch #TalentMAR https://t.co/BgjWGmxLHR

Impressive report in @NEJM. In a cohort of pregnant women with unusual clinical cfDNA-sequencing results, 52/107 were found to have a cancer via whole-body MRI, with a sensitivity of 98.0% and specificity of 88.5%. Physical exam & labs were of limited use. https://t.co/3EsjZ3qqZS

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: https://t.co/fEAbVvLFj0

We are thrilled to announce that the Peritoneal Surface Malignancies Surgery Unit at @hospitaldelmar is oficially admited into @GECOP_ @operarelcancer. Thank you all! @ccr_mar @MBonillaMbm @PatriciaSVelzq5 @SilviaSalvans @FBurdio

Enhorabuena Dra Clara Martinez Vila@althaiamanresa por Plenaria #SEOM24 de nuestro estudio ctDNA personalizado como marcador de respuesta duradera a #inmunoterapia en #melanoma avanzado. Gracias a Beca @_SEOM investigación en inmunooncología concedida @hospitalclinic@idibaps

Muchas gracias a vosotras. Un honor poder discutir un trabajo académicamente tan bonito e interessante Felicidades!

Muchas gracias @_SEOM por el PREMIO SEOM TESIS DOCTORAL para investigadores jóvenes y FELICIDADES a todos los premiados en las becas @_SEOM de este año, en especial a @JLinaresA, un orgullo compartir tus éxitos!

📸 Sin investigación, no hay avances, y por tanto, no hay beneficios para los pacientes con cáncer. Las 61 #BecasSEOM de investigación en cáncer, entregadas hoy en el @museoreinasofia, son fiel reflejo del potencial de la comunidad científica española en Oncología. ¡Enhorabuena!

#AcademicChatter #AcademicX

Els i les professionals del Servei d’#Oncologia al congrés de @myESMO El #TalentMAR amb l’equip de #càncer digestiu i els especialistes en tumors de cap i coll i de tumors genitourinaris #ESMO24 #OrgullMAR

Third line rechallenge with cetuximab and irinotecan in ctDNA selected mCRC 🔎Phs II CITRIC trial 👉ORR 0 vs 12% 👉DCR 44 vs 74% 👉PFS 2.2 vs 4.4 mo, p 0.255 🧐Trent to better outcome with Iri-Cetuxi rechallenge, potential option? @myESMO #ESMOAmbassadors

New publication suggesting the role of ATB in CRC recurrence ! Methodological framework to study real world health care system databases, and generate novel hypotheses on how ATB may modulate cancer outcomes. Great mentorship from @BenjcRousseau 🇺🇸🇫🇷 https://t.co/Xnxr7ryvNR

Treball en equip amb el pacient al centre. #rectalcancer @hospitaldelmar

Primera #transposicióuterina de l'Estat en una pacient amb #càncer de recte La tècnica permet a les dones afectades per un tumor a la zona pelviana mantenir la possibilitat de ser mares i evitar #menopausa precoç #obstetrícia @twigem2a @ester_miralpeix https://t.co/uj49VFDk6O

Just out the free version of the @GrupoMelanoma clinical trial of Encorafenib and binimetinib followed by RDT for patients with BRAFV600-mutant #melanoma and brain metastases (GEM1802/EBRAIN 🧠), published in @NeuroOnc .

Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn https://t.co/h7xgmjOfjz